✦ LIBER ✦

Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis

✍ Scribed by Marco Capobianco; Simona Malucchi; Stefano Ulisciani; Carmen Fava; Giovanna Rege Cambrin; Luigina Avonto; Giuseppe Saglio; Antonio Bertolotto

Publisher: Springer Milan
Year: 2008
Tongue: English
Weight: 42 KB
Volume: 29
Category: Article
ISSN: 1590-1874
DOI: 10.1007/s10072-008-0934-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acute myeloid leukaemia induced by mitox

Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient

✍ Radu Tanasescu; Marc Debouverie; Sophie Pittion; Rene Anxionnat; Herve Vespignan 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 113 KB

Single-dose mitoxantrone in combination

Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia

✍ Sung-Sook Lee; Je-Hwan Lee; Jung-Hee Lee; Dae-Young Kim; Se Hyung Kim; Sung-nam 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Fludarabine, cytarabine, and mitoxantron

Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG)

✍ Sebastian Giebel; Malgorzata Krawczyk-Kulis; Maria Adamczyk-Cioch; Beata Jakubas 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 136 KB

Pharmacology of cytarabine given as a co

Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia

✍ Fevzi Ozkaynak, M.; Avramis, Vassilios I.; Carcich, Sherri; Ortega, Jorge A. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 3 views

Background. The outcome of patients with acute myeloid leukemia (AML) who relapse or fail to achieve an initial remission has been dismal. Procedure. Fifteen pediatric patients with AML, 4 relapsed and 11 primary refractory, were reinduced with a loading bolus of 0.5 g/m 2 cytarabine (ara-C) followe

Antifungal treatment by amphotericin B a

Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia

✍ W. Hiddemann; M. E. Essink; W. Fegeler; M. Zühlsdorf; C. Sauerland; Th. Büchner 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 573 KB

Systemic fungal infections are recognized at increasing frequency during the course of intensive therapy for acute leukemias and require parenteral antifungal treatment mostly by amphotericin B (ampho B) alone or in combination with 5-Fluorocytosine (5-FC). Because of the potential myelosuppressive

In vitro-induced resistance to the deoxy

In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene

✍ A. P. A. Stegmann; M. W. Honders; A. Hagemeijer; B. Hoebee; R. Willemze; J. E. L 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 1018 KB